Global Immunoglobulin Market Forecast 2022-2030

The global immunoglobulin market is anticipated to rise with a CAGR of 6.87% across the forecast years of 2022 to 2030. The market's growth is strengthened by the increasing incidence of autoimmune disorders as well as immunodeficiency diseases, the rise in the geriatric populace, and the growing research and development activities.

MARKET INSIGHTS

Immunoglobulins are characterized as antibodies that are produced naturally by the body's immune system. They primarily help fight diseases and infections. These glycoprotein molecules are generated by plasma cells and also act as a pivotal component of the immune response of the body.

The rise in the geriatric population across the world is a leading factor expected to fuel the global immunoglobulin market growth over the forecasted years. As an individual ages, their immune system tends to deteriorate and responds relatively slower. This factor significantly increases the risk of sickness.

Moreover, the loss of adaptive immunity entailing older age not only makes a person more vulnerable to infections but also reactivates dormant pathogens that were formerly suppressed. As a result, the senior population is at a higher risk of an increased incidence of immunodeficiency diseases as well as the severity of certain infections. Hence, the growth in the elderly is set to augment the prevalence of age-related diseases, subsequently increasing the need for immunoglobulin products for their treatment.

REGIONAL INSIGHTS

The global immunoglobulin market growth assessment comprises the evaluation of North America, Europe, Asia-Pacific, and Rest of World. The Asia-Pacific is expected to be the fastest-growing region during the forecast years. The regional market's growth is mainly ascribed to the surging prevalence of different types of diseases, the increasing elderly population, and the surge in research and development.

COMPETITIVE INSIGHTS

The competitive rivalry within the global immunoglobulin market is intense and is anticipated to remain high during the forecast period. Furthermore, the presence of numerous leading market players across various regions facilitates a higher level of competition since the industry is fragmented. Some of the key players operating in the market are Pfizer Inc, Kamada Ltd, LFB Group, etc.

Our report offerings include:

Explore key findings of the overall market

Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)

Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions

Market Segmentation cater to a thorough assessment of key segments with their market estimations

Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share

Key analytics: Porter's Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.

Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.

Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments

Product Code: 46421

1. RESEARCH SCOPE & METHODOLOGY

1.1. STUDY OBJECTIVES
1.2. SCOPE OF STUDY
1.3. METHODOLOGY
1.4. ASSUMPTIONS & LIMITATIONS

2. EXECUTIVE SUMMARY

2.1. MARKET SIZE & ESTIMATES
2.2. MARKET OVERVIEW

3. MARKET DYNAMICS

3.1. KEY DRIVERS
- 3.1.1. GROWTH IN GERIATRIC POPULATION
- 3.1.2. PREVALENCE OF IMMUNODEFICIENCY DISEASES AND AUTOIMMUNE DISORDERS
- 3.1.3. INCREASING RESEARCH AND DEVELOPMENT ACTIVITIES
3.2. KEY RESTRAINTS
- 3.2.1. HIGH COST OF THERAPY
- 3.2.2. HIGH RISK OF SIDE EFFECTS

4. KEY ANALYTICS

4.1. IMPACT OF COVID-19 ON IMMUNOGLOBULIN MARKET
4.2. KEY MARKET TRENDS
4.3. PORTER'S FIVE FORCES ANALYSIS
- 4.3.1. BUYERS POWER
- 4.3.2. SUPPLIERS POWER
- 4.3.3. SUBSTITUTION
- 4.3.4. NEW ENTRANTS
- 4.3.5. INDUSTRY RIVALRY
4.4. OPPORTUNITY MATRIX
4.5. VENDOR LANDSCAPE
4.6. KEY BUYING CRITERIA
- 4.6.1. SOURCE
- 4.6.2. APPLICATION
- 4.6.3. EPITOPE
- 4.6.4. VALIDATION
4.7. REGULATORY FRAMEWORK

5. MARKET BY PRODUCT

5.1. IGG
5.2. IGA
5.3. IGM
5.4. IGE
5.5. IGD

6. MARKET BY MODE OF DELIVERY

6.1. INTRAVENOUS IMMUNOGLOBULIN
6.2. SUBCUTANEOUS IMMUNOGLOBULIN
6.3. INTRAMUSCULAR IMMUNOGLOBULIN

7. MARKET BY APPLICATION

7.1. HYPOGAMMA GLOBULINEMIA
7.2. CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY
7.3. PRIMARY IMMUNODEFICIENCY DISEASES
7.4. MYASTHENIA GRAVIS
7.5. MULTIFOCAL MOTOR NEUROPATHY
7.6. IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP)
7.7. INFLAMMATORY MYOPATHIES
7.8. SPECIFIC ANTIBODY DEFICIENCY
7.9. GUILLAIN-BARRE SYNDROME
7.10. OTHER APPLICATIONS

8. MARKET BY DISTRIBUTION CHANNEL

8.1. HOSPITAL PHARMACY
8.2. SPECIALTY PHARMACY
8.3. OTHER DISTRIBUTION CHANNELS

9. MARKET BY END-USER

9.1. HOSPITALS & CLINICS
9.2. HOMECARE

10. GEOGRAPHICAL ANALYSIS

10.1. NORTH AMERICA
- 10.1.1. MARKET SIZE & ESTIMATES
- 10.1.2. KEY GROWTH ENABLERS
- 10.1.3. KEY CHALLENGES
- 10.1.4. KEY PLAYERS
- 10.1.5. COUNTRY ANALYSIS
  - 10.1.5.1. UNITED STATES
  - 10.1.5.2. CANADA
10.2. EUROPE
- 10.2.1. MARKET SIZE & ESTIMATES
- 10.2.2. KEY GROWTH ENABLERS
- 10.2.3. KEY CHALLENGES
- 10.2.4. KEY PLAYERS
- 10.2.5. COUNTRY ANALYSIS
  - 10.2.5.1. UNITED KINGDOM
  - 10.2.5.2. GERMANY
  - 10.2.5.3. FRANCE
  - 10.2.5.4. SPAIN
  - 10.2.5.5. ITALY
  - 10.2.5.6. NORDIC COUNTRIES
  - 10.2.5.7. REST OF EUROPE
10.3. ASIA-PACIFIC
- 10.3.1. MARKET SIZE & ESTIMATES
- 10.3.2. KEY GROWTH ENABLERS
- 10.3.3. KEY CHALLENGES
- 10.3.4. KEY PLAYERS
- 10.3.5. COUNTRY ANALYSIS
  - 10.3.5.1. CHINA
  - 10.3.5.2. JAPAN
  - 10.3.5.3. INDIA
  - 10.3.5.4. SOUTH KOREA
  - 10.3.5.5. INDONESIA
  - 10.3.5.6. THAILAND
  - 10.3.5.7. VIETNAM
  - 10.3.5.8. AUSTRALIA
  - 10.3.5.9. REST OF ASIA-PACIFIC
10.4. REST OF WORLD
- 10.4.1. MARKET SIZE & ESTIMATES
- 10.4.2. KEY GROWTH ENABLERS
- 10.4.3. KEY CHALLENGES
- 10.4.4. KEY PLAYERS
- 10.4.5. REGIONAL ANALYSIS
  - 10.4.5.1. LATIN AMERICA
  - 10.4.5.2. MIDDLE EAST & AFRICA

11. COMPETITIVE LANDSCAPE

11.1. KEY STRATEGIC DEVELOPMENTS
- 11.1.1. MERGERS & ACQUISITIONS
- 11.1.2. PRODUCT LAUNCHES & DEVELOPMENTS
- 11.1.3. PARTNERSHIPS & AGREEMENTS
- 11.1.4. BUSINESS EXPANSIONS & DIVESTITURES
11.2. COMPANY PROFILES
- 11.2.1. ADMA BIOLOGICS
- 11.2.2. BIO PRODUCTS LABORATORY
- 11.2.3. BIOTEST AG
- 11.2.4. CHINA BIOLOGIC PRODUCTS INC
- 11.2.5. CSL BEHRING
- 11.2.6. GRIFOLS SA
- 11.2.7. KAMADA LTD
- 11.2.8. KEDRION BIOPHARMA
- 11.2.9. LFB GROUP
- 11.2.10. OCTAPHARMA AG
- 11.2.11. PFIZER INC
- 11.2.12. SANQUIN PLASMA PRODUCTS BV
- 11.2.13. SHANGHAI RAAS BLOOD PRODUCTS CO LTD
- 11.2.14. SICHUAN YUANDA SHUYANG PHARMACEUTICAL CO LTD
- 11.2.15. TAKEDA PHARMACEUTICAL COMPANY LIMITED